



The TIMI Trials

ENTIRE-TIMI 23

OBJECTIVE: To assess the safety and efficacy of enoxaparin as an adjunct to thrombolysis with or without GP IIb/IIIa therapy among patients presenting with ST elevation myocardial infarction.

1. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JC, Hamer B, Bassand JP, Bigonzi F, Pisapia G, Gibson CM, Heidbuchel H, Braunwald E, Van de Werf F. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. *Circulation*. 2002;105:1642-9.
2. Morrow DA, Rifai N, Bassand JP, Bigonzi F, Pisapia G, Van de Werf F, Antman EM. Enoxaparin attenuates the rise in von willebrand factor after fibrinolysis for ST-elevation myocardial infarction: Results from ENTIRE-TIMI 23. *Eur Heart J* 2002; Supp I.
3. Morrow DA, Rifai N, Bigonzi F, Bassand JP, Pisapia G, Hecquet C, Van de Werf F, Antman EM. Enoxaparin attenuates the rise in Von Willebrand factor in patients with ST-segment elevation myocardial infarction treated with fibrinolysis: results from ENTIRE-TIMI 23. *Eur Heart J*. 2002;23 (Abstr suppl):506.
4. Mega JL, Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Rifai N, Gibson CM, Antman EM, Braunwald E. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI 23 substudy. *J Am Coll Cardiol* 2004;44:335-9.
5. Gibson CM, Jennings LK, Lorenz D, Giugliano RP, Harrington RA, Roe MT, Murphy SA, Cholera S, Baran KW, Hobbach H, Braunwald E. Increased platelet receptor occupancy following eptifibatid therapy is associated with improved patency, tissue level perfusion and ST segment resolution in ST segment elevation myocardial infarction: An INTEGRITI substudy. *Circulation* 2004;110(6):679-84
6. Gibson CM, Murphy SA, Morrow DA, Aroesty JM, Gibbons RJ, Goulay SG, Barron HV, Giugliano RP, Antman EM, Braunwald E. Angiographic Perfusion Score: An Angiographic Variable That Integrates Both Epicardial and Tissue Level Perfusion Before and After Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. *American Heart Journal* 2004;148(2):336-40.
7. Shimp M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. *Circulation* 2004;109:186-190.
8. Gelfand EV, Morrow DA, Sabatine MS, Rifai N, Murphy SA, McCabe CH, Antman EM. Risk Stratification in STEMI with multiple biomarkers. *J Am Coll Cardiol* 2004;44(5):259A.
9. Ray KK, Morrow D, Murphy S, McCabe C, Antman E, Braunwald E, Gibson CM. Changes in soluble markers of endothelial function correlate with TIMI flow grade and corrected TIMI frame count after fibrinolysis. An ENTIRE TIMI 23 substudy. *Circulation* 2004;110:III-660.
10. Ray KK, Morrow D, Gibson CM, Murphy S, Antman EM, Braunwald E for the ENTIRE-TIMI 23 Study Group. Predictors of the rise in vWF after ST elevation myocardial infarction: Implications for treatment strategies and clinical outcome. *Eur Heart J* 2005;26:440-446.